Telehealth has become the dominant channel for GLP-1 prescriptions. Over a dozen platforms now offer consultations, prescribing, and home delivery — all without an in-person visit. But they're not equal. Pricing, provider quality, medication options, and ongoing support vary dramatically.
We evaluated the leading telehealth GLP-1 providers accepting patients in May 2026. Here's what we found.
Top Tier: Best Overall Value
Explore consultation access and weight-management options. Confirm which fees include medication.
Explore Sesame Care ↗Medication, legal availability, provider credentials and full price require verification; compounded medications are not FDA-approved.Embody
Enhance MD
Oak Longevity
Wellorithm
Strong Mid-Range Options
Review program enrollment, whether medication is compounded, dispensing pharmacy information, and the total ongoing price.
Explore Gala GLP-1 ↗Eligibility and prices must be verified directly. Compounded GLP-1 products are not FDA-approved.Explore care options, follow-up services and pricing. Confirm medication type and total fees.
Explore Ivim Health ↗Medication, legal availability, provider credentials and full price require verification; compounded medications are not FDA-approved.Review its telehealth eligibility process, treatment options, follow-up care and recurring charges.
Explore Oak GLP-1 ↗Medication, legal availability, provider credentials and full price require verification; compounded medications are not FDA-approved.Direct Meds
Explore available weight-management program types and confirm the exact medication, pharmacy and recurring charges.
Explore GobyMeds ↗Medication, legal availability, provider credentials and full price require verification; compounded medications are not FDA-approved.Budget-Friendly
Sprout Health
Strut Health
Brand-Name Access
Sesame Care
Active But Flagged
MEDVi
Regulatory Watch: May 2026
The FDA proposed removing semaglutide, tirzepatide, and liraglutide from the drug shortage bulks list on April 30, 2026 — with comments due June 29, 2026. This could affect compounding pharmacies' ability to produce these medications. Patients considering telehealth GLP-1 programs should be aware of this regulatory timeline.
Compare all telehealth GLP-1 providers side by side
Full Comparison →Sources
- Provider pricing and program details verified via provider websites, May 2026.
- FDA Drug Shortage Bulks List Proposal — April 30, 2026. Public comment period through June 29, 2026.
- FDA Warning Letter to MEDVi — February 2026, misbranding violations.
- LegitScript verification database. 503A/503B pharmacy registration records.
Affiliate Disclosure: Some links on this page are affiliate links and may generate compensation. This does not influence our editorial content.